GCTK News & Events

Glucotrack provided a recap of the critical operational milestones which have positioned the company to submit an IDE to the FDA for its continuous blood glucose monitoring technology, with a goal to file requisite documents with the FDA during Q2. "In 2025 we made meaningful progress in advancing the development of our fully implantable continuous blood glucose monitoring technology and strengthening Glucotrack's foundation," commented Paul Goode, president and CEO of Glucotrack. "The completion of our first-in-human study in Brazil and initiation of our follow up study in Australia enables us to advance toward our U.S. clinical program. With trial infrastructure in place and product enhancements completed, we are prepared to initiate the study, pending FDA approval."

Glucotrack announced that the US Patent and Trademark Office, USPTO, has issued Patent Nos. US 12,453,494, US 12,458,257, and US 12,458,258 for the Company's continuous blood glucose monitoring, CBGM, platform. The patents strengthen Glucotrack's competitive position and intellectual property protection as the Company advances its multi-year, fully implantable CBGM system toward commercialization. "These patents represent a significant milestone in protecting our innovative technology that is at the core of our CBGM system," said Paul Goode, PhD, President and Chief Executive Officer of Glucotrack. "Securing our intellectual property is fundamental to our strategy as we advance our fully implantable, long-term sensor through further clinical testing and toward commercialization. These patents establish important competitive barriers and strengthen our position to deliver a differentiated approach to diabetes management."

Glucotrack entered into a securities purchase agreement with a single institutional investor for the purchase and sale of 1,033,591 shares of common stock and warrants to purchase up to 2,067,182 shares of common stock at an effective combined price of $3.87 per share and common warrant for aggregate gross proceeds of approximately $4M, before deducting placement agent fees and other offering expenses. The warrants will have an exercise price of $3.87 per share, will not be exercisable until receipt of shareholder approval and will expire five years from the initial exercise date. The closing of the offering is expected to occur on or about December 31, 2025, subject to the satisfaction of customary closing conditions. Curvature Securities is acting as the sole placement agent in connection with the offering.